azoxymethane has been researched along with celecoxib in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 8 (66.67) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Kawamori, T; Rao, CV; Reddy, BS; Seibert, K | 1 |
| Hirose, Y; Kelloff, G; Lubet, R; Paulson, S; Rao, CV; Reddy, BS; Seibert, K; Steele, V | 1 |
| Hara, A; Hirose, Y; Katayama, M; Kuno, T; Mori, H; Qiao, Z; Shimizu, M; Yamada, Y; Yoshimi, N | 1 |
| Connor, JR; Indranie, C; Manning, PT; Rao, CV; Reddy, BS; Simi, B | 1 |
| Li, Y; Lubet, RA; Pereira, MA; Steele, VE; Tao, L; Umar, A; Wang, W | 1 |
| Barnard, GF; Do, K | 1 |
| Patlolla, JM; Rao, CV; Reddy, BS; Simi, B; Wang, SH | 1 |
| Khor, TO; Kong, AN; Kopelovich, L; Rao, CV; Reddy, BS; Steele, VE; Wang, CX; Zheng, X | 1 |
| Guruswamy, S; Kopelovich, L; Patlolla, JM; Rao, CV; Steele, VE; Swamy, MV | 1 |
| Alam, F; Byun, Y; Chung, SW; Jeon, OC; Kim, JY; Kim, SY; Park, J; Son, WC | 1 |
| Barnholtz-Sloan, JS; Chen, Y; Dawson, DM; Fink, SP; Kopelovich, L; Kresak, A; Lawrence, EG; Markowitz, SD; Willis, JE; Yang, P; Zhang, Y | 1 |
| Bi, X; Buraschi, S; Chen, Y; Fan, D; Iozzo, RV; Mao, L; Yang, J; Yue, J; Zhang, Q; Zhou, H | 1 |
12 other study(ies) available for azoxymethane and celecoxib
| Article | Year |
|---|---|
Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis.
Topics: Animals; Anticarcinogenic Agents; Azoxymethane; Celecoxib; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Intestinal Mucosa; Isoenzymes; Male; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Inbred F344; Sulfonamides | 1998 |
Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis.
Topics: Administration, Oral; Animals; Anticarcinogenic Agents; Azoxymethane; Celecoxib; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease Progression; Isoenzymes; Male; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Inbred F344; Sulfonamides; Time Factors | 2000 |
Suppression of occurrence and advancement of beta-catenin-accumulated crypts, possible premalignant lesions of colon cancer, by selective cyclooxygenase-2 inhibitor, celecoxib.
Topics: Animals; Anticarcinogenic Agents; Azoxymethane; beta Catenin; Celecoxib; Cell Division; Cell Nucleus; Colonic Neoplasms; Cyclooxygenase 2; Cytoskeletal Proteins; Enzyme Inhibitors; Immunohistochemistry; Isoenzymes; Male; Nucleolus Organizer Region; Precancerous Conditions; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Inbred F344; Sulfonamides; Time Factors; Trans-Activators | 2001 |
Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
Topics: Animals; Anticarcinogenic Agents; Azoxymethane; Body Weight; Carcinogens; Celecoxib; Colon; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Double-Blind Method; Drug Synergism; Enzyme Inhibitors; Homoarginine; Intestinal Mucosa; Isoenzymes; Male; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Random Allocation; Rats; Rats, Inbred F344; Sulfonamides | 2002 |
Modulation by celecoxib and difluoromethylornithine of the methylation of DNA and the estrogen receptor-alpha gene in rat colon tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azoxymethane; Biomarkers, Tumor; Carcinogens; Celecoxib; Colon; Colonic Neoplasms; CpG Islands; Diet; DNA Methylation; Eflornithine; Estrogen Receptor alpha; Male; Pyrazoles; Rats; Rats, Inbred F344; Receptors, Estrogen; RNA, Messenger; Sulfonamides | 2004 |
Effect of concomitant polyethylene glycol and celecoxib on colonic aberrant crypt foci and tumors in F344 rats.
Topics: Animals; Azoxymethane; Bromodeoxyuridine; Celecoxib; Colon; Colonic Neoplasms; Cyclooxygenase Inhibitors; Cytoprotection; Drug Synergism; Female; Immunohistochemistry; Male; Polyethylene Glycols; Pyrazoles; Rats; Rats, Inbred F344; Staining and Labeling; Sulfonamides | 2005 |
Prevention of colon cancer by low doses of celecoxib, a cyclooxygenase inhibitor, administered in diet rich in omega-3 polyunsaturated fatty acids.
Topics: Animals; Azoxymethane; Carcinogens; Celecoxib; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diet; Dose-Response Relationship, Drug; Fatty Acids, Omega-3; Male; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Inbred F344; Sulfonamides | 2005 |
Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats.
Topics: Animals; Anticarcinogenic Agents; Apoptosis; Aspirin; Atorvastatin; Azoxymethane; Carcinogens; Celecoxib; Cell Growth Processes; Colonic Neoplasms; Dose-Response Relationship, Drug; Heptanoic Acids; Male; Pyrazoles; Pyrroles; Rats; Rats, Inbred F344; Sulfonamides | 2006 |
Inhibition of azoxymethane-induced colorectal cancer by CP-31398, a TP53 modulator, alone or in combination with low doses of celecoxib in male F344 rats.
Topics: Adenocarcinoma; Animals; Apoptosis; Azoxymethane; Blotting, Western; Carcinogens; Celecoxib; Cell Proliferation; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Drug Therapy, Combination; Immunoenzyme Techniques; In Situ Nick-End Labeling; Male; Maximum Tolerated Dose; Membrane Proteins; Pyrazoles; Pyrimidines; Rats; Rats, Inbred F344; Sulfonamides; Tumor Suppressor Protein p53 | 2009 |
Combinational chemoprevention effect of celecoxib and an oral antiangiogenic LHD4 on colorectal carcinogenesis in mice.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Anticarcinogenic Agents; Azoxymethane; Carcinogenesis; Celecoxib; Colon; Colonic Polyps; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Deoxycholic Acid; Dextran Sulfate; Drug Therapy, Combination; Heparin, Low-Molecular-Weight; Inflammation; Male; Mice, Inbred ICR; Neovascularization, Pathologic; Pyrazoles; Sulfonamides; Tumor Burden | 2014 |
Sulindac reversal of 15-PGDH-mediated resistance to colon tumor chemoprevention with NSAIDs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Azoxymethane; Carcinogens; Celecoxib; Chemoprevention; Colonic Neoplasms; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Hydroxyprostaglandin Dehydrogenases; Inflammation; Intestinal Mucosa; Membrane Proteins; Mice; Mice, Knockout; Pyrazoles; Sulfonamides; Sulindac | 2015 |
Decorin deficiency promotes epithelial-mesenchymal transition and colon cancer metastasis.
Topics: Animals; Azoxymethane; beta Catenin; Cadherins; Cancer-Associated Fibroblasts; Celecoxib; Colitis-Associated Neoplasms; Colonic Neoplasms; Decorin; Epithelial-Mesenchymal Transition; Extracellular Matrix; Humans; Mice; Neoplasm Metastasis; Proteoglycans; Tumor Microenvironment | 2021 |